文献速递头痛与眩晕

氨茶碱治疗硬膜穿刺后头痛:一项随机临床试验

Aminophylline for treatment of postdural puncture headache: A randomized clinical trial.
PubMed 文献 · Neurology · 2018-03-23

这项在中国5个中心开展的随机临床试验纳入126例硬膜穿刺后头痛患者,比较静脉给予氨茶碱250 mg与安慰剂(每日一次、连续2天)的疗效。结果显示氨茶碱组治疗后8小时平均VAS评分显著低于安慰剂组(5.34 vs 2.98,p < 0.001),PGIC改善率更高(72.6% vs 39.1%,p < 0.01),不良事件发生率无显著差异。

要点

  • 氨茶碱组治疗后8小时平均VAS评分5.34,安慰剂组2.98,差异有统计学意义。
  • 氨茶碱组PGIC改善率72.6%,安慰剂组39.1%,差异有统计学意义。
  • 两组不良事件发生率无显著差异(4.8% vs 1.6%,p = 0.589)。

核心结论

  • 静脉氨茶碱是硬膜穿刺后头痛患者有效且安全的早期治疗。
  • 该研究提供I级证据表明静脉氨茶碱可减轻硬膜穿刺后头痛的严重程度。

研究设计与样本

  • 随机临床试验,在中国5个中心纳入126例硬膜穿刺后头痛患者,氨茶碱组62例、安慰剂组64例。
  • 在症状出现3小时内随机给予静脉氨茶碱250 mg或安慰剂,每日一次,连续2天。
  • 主要终点为治疗后8小时头痛严重程度,采用站立位视觉模拟量表(VAS)评分评估,并进行意向性治疗分析。

主要发现

  • 氨茶碱组治疗后8小时平均VAS评分5.34,安慰剂组2.98,氨茶碱组显著低于安慰剂组(p < 0.001)。
  • 氨茶碱组PGIC改善率72.6%,安慰剂组39.1%,氨茶碱组显著高于安慰剂组(p < 0.01)。
  • 治疗效果在30分钟时间点已显现,并持续2天。
  • 不良事件发生率氨茶碱组4.8%,安慰剂组1.6%,两组无显著差异(p = 0.589)。
  • 患者中位年龄37岁,女性96例(76.2%)。

临床怎么用

  • 原文结论认为静脉氨茶碱是硬膜穿刺后头痛有效且安全的早期治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy and safety of IV aminophylline for patients with postdural puncture headache (PDPH). METHODS: We randomly assigned patients to groups receiving either 250 mg IV aminophylline or a placebo within 3 hours of symptom onset once daily for 2 consecutive days. The primary endpoint was headache severity 8 hours after treatment. We assessed this using visual analog scale (VAS) scores taken from patients in a standing position. We also recorded posttreatment VAS score changes, Patient Global Impression of Change (PGIC) scores, and adverse events. We performed an intention-to-treat analysis. RESULTS: We enrolled 126 patients with PDPH at 5 centers in China (62 assigned to the aminophylline group and 64 to the placebo group). The median age was 37 years, and 96 (76.2%) patients were women. Compared to the placebo-treated patients, the aminophylline-treated patients had significantly lower mean VAS scores 8 hours after treatment (5.34 vs 2.98, p < 0.001) and were significantly more likely to report improvements on the PGIC (39.1% vs 72.6%, p < 0.01). This therapeutic effect was already evident at the 30-minute time point and persisted for 2 days. There was no significant difference in the incidence of adverse events (4.8% vs 1.6%, p = 0.589). CONCLUSIONS: IV aminophylline is an effective and safe early-stage treatment for patients with PDPH. CLINICALTRIALSGOV IDENTIFIER: NCT02522013. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for people with PDPH, IV aminophylline reduces headache severity.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Wu C, Guan D, Ren M, et al. Aminophylline for treatment of postdural puncture headache: A randomized clinical trial. Neurology. 2018. PMID: 29572284. doi:10.1212/WNL.0000000000005351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。